Scientists assessed the safety and clinical activity of ciltacabtagene autoleucel, a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or refractory multiple myeloma with poor prognosis.
[Lancet]
7992332
{7992332:FXN44LID}
apa
50
1
163964
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/